ERBB2 and breast carcinoma: Stratified by type of CDK 4/6 inhibitor, the incidence rates of all-grade nephrotoxic AEs among patients with HR+/HER2-breast cancer treated with abemaciclib, palbociclib, ribociclib, and dalpiciclib were 10.60% (410/3,868), 7.58% (372/4,907), 8.85% (102/1,152), and 11.81% (64/542), respectively.